The Top20 Drugs by Sales, by Packages sold

Pill Nation: Are Americans Over-Medicated?

Are Americans Over-Medicated?

The Top20 Drugs by Sales and by Packages sold infographic
Pill Nation : The Top20 Drugs by Sales and by Packages sold

The Top20 Drugs by Sales and by Packages sold

American is a nation of pill poppers. Nearly 13 prescriptions were prescribed per man, woman, and child last year. We’re one of only two countries in the world who allow direct-to-consumer Rx advertising; and Rx have slowly grown to be the third highest medical cost. Welcome to the pill nation.
Sources and full article on TheNursingBible and Janice_Flahiff on WordPress.

Find More Information:

All our posts about AEDsbig pharmaDESdoctorsdrug money,drugsEx Pharma Rx Drug Pusher Confessions – Gwen Olsen, the FDAmedical representativesSSRIsthalidomidevalproate. See more infographics.

On Flickr®

The more Weight a Woman gains during Pregnancy, the higher the Risk to have a Child with Autism

The observed associations were particularly pronounced in male children

Abstract

image of Jama Network
@JAMAPeds : editorial team of pediatricians and researchers passionate about child health research; part of the newly formed JAMA Network Pediatrics

Importance
One in 88 children in the United States is diagnosed as having autism spectrum disorder. Significant interest centers on understanding the environmental factors that may contribute to autism risk.

Objective
To examine whether induced (stimulating uterine contractions prior to the onset of spontaneous labor) and/or augmented (increasing the strength, duration, or frequency of uterine contractions with spontaneous onset of labor) births are associated with increased odds of autism.

Design, Setting, and Participants
We performed an epidemiological analysis using multivariable logistic regression modeling involving the North Carolina Detailed Birth Record and Education Research databases. The study featured 625 042 live births linked with school records, including more than 5500 children with a documented exceptionality designation for autism.

Exposures
Induced or augmented births.

Main Outcomes and Measures
Autism as assessed by exceptionality designations in child educational records.

Results
Compared with children born to mothers who received neither labor induction nor augmentation, children born to mothers who were induced and augmented, induced only, or augmented only experienced increased odds of autism after controlling for potential confounders related to socioeconomic status, maternal health, pregnancy-related events and conditions, and birth year. The observed associations between labor induction/augmentation were particularly pronounced in male children.

Conclusions and Relevance
Our work suggests that induction/augmentation during childbirth is associated with increased odds of autism diagnosis in childhood. While these results are interesting, further investigation is needed to differentiate among potential explanations of the association including underlying pregnancy conditions requiring the eventual need to induce/augment, the events of labor and delivery associated with induction/augmentation, and the specific treatments and dosing used to induce/augment labor (eg, exogenous oxytocin and prostaglandins).

Sources

Association of Autism With Induced or Augmented Childbirth in North Carolina Birth Record (1990-1998) and Education Research (1997-2007) Databases

Roles of p63 in the DiEthylStilbestrol-induced CervicoVaginal Adenosis

Women exposed to DES in utero develop abnormalities, including cervicovaginal adenosis that can lead to cancer

Abstract
PubMed logo image
Women exposed to diethylstilbestrol (DES) in utero develop abnormalities, including cervicovaginal adenosis that can lead to cancer.

Women exposed to diethylstilbestrol (DES) in utero develop abnormalities, including cervicovaginal adenosis that can lead to cancer. We report that transient disruption of developmental signals by DES permanently changes expression of p63, thereby altering the developmental fate of Müllerian duct epithelium. The cell fate of Müllerian epithelium to be columnar (uterine) or squamous (cervicovaginal) is determined by mesenchymal induction during the perinatal period. Cervicovaginal mesenchyme induced p63 in Müllerian duct epithelium and subsequent squamous differentiation. In p63(-/-) mice, cervicovaginal epithelium differentiated into uterine epithelium. Thus, p63 is an identity switch for Müllerian duct epithelium to be cervicovaginal versus uterine. P63 was also essential for uterine squamous metaplasia induced by DES-exposure. DES-exposure from postnatal day 1 to 5 inhibited induction of p63 in cervicovaginal epithelium via epithelial ERalpha. The inhibitory effect of DES was transient, and most cervicovaginal epithelial cells recovered expression of p63 by 2 days after discontinuation of DES-treatment. However, some cervicovaginal epithelial cells failed to express p63, remained columnar and persisted into adulthood as adenosis.

Sources

NCBI, PMID: 14998922, Apr 2004 – Full article The Company of Biologists Limited 131/7/1639 15 Dec 2003.

More DES DiEthylStilbestrol Resources

OverDiagnosis and Prescription Drugs: an Interview with Peter Gøtzsche

Prescription drugs are the third leading cause of death after heart disease and cancer…

Interview with Peter Gøtzsche – Co-Founder of The Cochrane Collaboration, and Director of the Nordic Cochrane Center in Copenhagen, Denmark – on the topic of his book Deadly Medicines and Organized Crime: How Big Pharma has Corrupted Healthcare as featured on Mad In America.

More info and Videos

I don’t have the right to cancer care !?

All people have the right to access proven and effective cancer treatments and services on equal terms, and without suffering hardship as a consequence

Debunk the Cancer Myths

poster of Cancer Myth 4 I don't have the right to cancer care
Cancer Myth 4: get involved, download the poster, postcard and fact sheet.

Truth:

All people have the right to access proven and effective cancer treatments and services on equal terms, and without suffering hardship as a consequence.

Find More Information:

On Flickr®

Chemotherapy FDA-Approved Anti-Cancer Drugs possibly leading to Tumor Recurrence

Systematic screen of chemotherapeutics in Drosophila stem cell tumors

Abstract
image of Michele Markstein
Michele Markstein, University of Massachusetts Amherst molecular biologist, who led the research

” In this article we report a large-scale chemical screen in adult Drosophila to find inhibitors of stem-cell–derived tumors. To our surprise, we found that some Food and Drug Administration-approved chemotherapy drugs have the dual property of reducing growth of stem-cell–derived tumors while also stimulating hyperproliferation of their wild-type counterparts. Since hyperproliferation is one of the hallmarks of cancer cells, this side effect could contribute to refueling the growth of the very tumors that these chemotherapeutics are intended to inhibit. We show that this side effect is driven by the evolutionarily conserved Janus kinase-signal transducers and activators of transcription (JAK-STAT) inflammatory pathway, raising the possibility that the JAK-STAT pathway may also be activated in humans who are treated with some chemotherapeutics. ”

Sources and More Information

Bisphenol-A and DiEthylStilbestrol Exposure linked to Breast Cancer Tumor Growth

BPA and DES exposure induces the expression of breast cancer associated long noncoding RNA HOTAIR in vitro and in vivo

Medical Xpress logo
Medical Xpress latest research news on health and medicine talks about a new study linking BPA and breast cancer tumor growth

UT Arlington biochemists say their newly published study brings researchers a step closer to understanding how the commonly used synthetic compound bisphenol-A, or BPA, may promote breast cancer growth.

Researchers saw similar results when they exposed HOTAIR to a synthetic estrogen called diethylstilbestrol (DES). DES has been shown to increase risks of breast cancer and other health problems in women who used it and their daughters. It was formerly used as a hormone replacement and as an attempt to prevent pregnancy complications.

Sources and More Information
More DES DiEthylStilbestrol Resources

Prescription Drugs Cost and Big Pharma: how the Lobbies rule America

The astronomically high health care costs in the United States explained…

You really think that you have a say in how your government functions, think again. This report describes a shocking revolving door system that works beyond our control.
The amount of money spent on lobbying and political contributions by the pharmaceutical industry has continued to increase since.
It is why you can’t pay your medical bills.
And it is happening behind the scenes so you never see it.
This report is a rare glimpse into how we lost our democracy.

More info and Videos

Omerta dans les Labos Pharmaceutiques: Confessions d’un Médecin

Un médecin au service des labos vide son sac

Description de l’ouvrage

Omerta dans les labos pharmaceutiques, book image
Les pratiques du laboratoire pharmaceutique Merck en accusation.

Alors que l’actualité a révélé au grand jour des scandales médicamenteux, le docteur Bernard Dalbergue brise la loi du silence. Cet ancien cadre qui a travaillé pour plusieurs laboratoires pharmaceutiques dévoile une des causes de ces drames : le soutien d’experts médicaux rémunérés peut biaiser la politique de santé. Un secret de famille souvent tu. Le jour où il a refusé de jouer le jeu, la carrière du docteur Dalbergue s’est arrêtée net. Son témoignage, sincère et percutant, dresse un constat terrible : obnubilée par un marketing débridé, surfant sur les failles du système de sécurité du médicament, l’industrie perd parfois de vue sa mission principale, soigner. La journaliste Anne-Laure Barret étoffe ce récit d’une enquête où elle revisite le scandale oublié du Vioxx et montre comment le vaccin Gardasil a été recommandé à la population contre l’avis de nombreux spécialistes.

  • Première partie : témoignage de Bernard DALBERGUE.
  • Deuxième partie : Deux enquêtes de Anne Laure BARRET sur le Vioxx® et le vaccin Gardasil® (87 pages), 2 produits phares du dernier employeur de B DALBERGUE et qui posent des questions3.
  • Sources AmazonFr. – Lire des extraits.

Articles de Presse

  • Un médecin au service des labos vide son sac
    Liberation, 03-02-2014.
  • Les labos versent de très grosses sommes aux leaders d’opinion
    Le Nouvel Observateur, 04-02-2014.
  • Les pratiques du laboratoire pharmaceutique Merck en accusation
    Le Monde, 04-02-2014.
  • Le Dr Bernard Dalbergue déenonce les méthodes immorales des laboratoires pharmaceutiques, France Info, 05-02-2014.
  • Omerta dans les labos pharmaceutiques
    Formindep, 10-02-2014.

En savoir plus sur ce Sujet

Sur Flickr®

Outcome and Follow-Up of DiEthylStilbestrol-Exposed Individuals

DES remains the only firmly established transplacental carcinogen in humans ; it’s important to continue to monitor exposed offspring for long-term health effects

image of DES-affected
DES remains the only firmly established transplacental carcinogen in humans. Because of this risk, it is important to continue to monitor exposed offspring and their mothers for long-term health effects. DES is also important as the model agent for endocrine disrupting chemicals and their effects on fetal development and adult health.
2014 Study Abstract

Diethylstilbestrol (DES) is a nonsteroidal estrogen first synthesized in 1938. It readily crosses the placenta. Exposure to DES during a critical period of organogenesis disorganizes the developing uterine muscle layers; causes maldevelopment of the uterotubal junction; and prevents stratification of the vaginal epithelium and resorption of vaginal glands, resulting in vaginal adenosis. In murine studies, the mechanism for DES-induced adenosis is blocked expression of Trp63 in Müllerian duct epithelium at epithelial estrogen receptor alpha. DES has also been shown to alter normal programming of the gene families Hox and Wnt, which affect differentiation of the reproductive tract.
DES was initially used for postpartum lactation suppression and treatment of postmenopausal symptoms, but quickly became an accepted intervention for prevention of miscarriage, premature birth, and other pregnancy problems. It is estimated that five million pregnant women worldwide received DES to improve pregnancy outcome. Although clinical trials in the 1950s demonstrated that it was ineffective for prevention of adverse pregnancy outcomes, it remained in use until 1971 in the United States and until the early 1980s in some other countries. In 1971, in-utero exposure to DES was linked to the occurrence of vaginal clear cell adenocarcinoma in female offspring, which prompted the US Food and Drug Administration (FDA) to advise against its use in pregnancy. Subsequently, other health effects, such as pregnancy complications and male genitourinary tract abnormalities, were also linked to in-utero DES exposure. DES is no longer commercially available for human use in North America.

DES remains the only firmly established transplacental carcinogen in humans. Because of this risk, it is important to continue to monitor exposed offspring and their mothers for long-term health effects. DES is also important as the model agent for endocrine disrupting chemicals and their effects on fetal development and adult health. Aberrant DNA methylation has been proposed as a molecular mechanism whereby endocrine disruptors such as DES regulate developmental programming.

Sources
More DES DiEthylStilbestrol Resources